Chem Soc Rev 37:1174–1187 Suntharalingam K, Hunt DJ, Duarte AA, White AJP, Mann DJ, Vilar R (2012) A tri-copper(II) complex displaying DNA-cleaving properties and antiproliferative activity against cancer cells. Chem Eur J 18:15133–15141PubMedCrossRef Szczepanik W,
Kaczmarek P, Sobczak J, Bal W, Gatner K, Jeżowska-Bojczuk M (2002) Copper(II) binding by kanamycin A and hydrogen peroxide activation by resulting complexes. New J Chem 26:1507–1514CrossRef Yoon SA, Choi JR, Kim JO, Shin JY, Zhang X, Kang JH (2010) Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced see more cytotoxicity. Cancer Res Treat 42:163–171PubMedCentralPubMedCrossRef Zowczak Givinostat order M, Iskra M, Torlinski L, Cofta S (2001) Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res 82:1–8PubMedCrossRef”
“Introduction The rapid spread of cancer has sparked an intense worldwide search for new compounds, which may be used in designing anticancer drugs. The search of more effective anticancer agent has focused to a large extent on the design of molecules capable of recognizing and binding to PFT�� manufacturer target DNA base sequences. Development of anticancer drugs with fewer or no side effects is important for the treatment
for cancer. The search for such potential anticancer drugs has led to the discovery of synthetic small molecules with anti-carcinogenic activity and limited harmful side effects particularly with respect to the immune system. Research in this area is expanding rapidly, and some promising leads have emerged. Heterocyclic moieties can be found
in a large number of compounds, which display biological activity. The biological activity of the compounds is mainly dependent on their molecular structures (Salimon et al., 2010). A vast number of 1,3,4-thiadiazoles have been reported as potential pharmacologically active compounds with antimicrobial Suplatast tosilate (Patil and Biradar, 2001; Zamani et al., 2004; Sharma et al., 2006), antiviral (Pandey et al., 2004), antitubercular (Oruc et al., 2004; Desai et al., 1984), anticonvulsant (Shrivastava et al., 1999; Kumar et al., 2003; Gupta et al., 2008; Stillings et al., 1986; Jatav et al., 2008), CNS depressant (Jatav et al., 2008), hypoglycaemic (Hanna et al., 1995; Pattan et al., 2009), anti-inflammatory (Sharma et al., 2008; Varandas et al., 2005) and anticancer (Noolvi et al., 2011; Kumar et al., 2010) properties. At the same time, the 1,3,4-thiadiazole fragment appears in a number of clinically used drugs such as acetazolamide; methazolamide; butazolamide (diuretic); sulfamethiazole (antibacterial); cefazolin, cefazedone (antibiotic); atibeprone (anti-depressant); glybuthiazole, glybuzole (antidiabetic); and tebuthiuron (insecticide) (Wilson and Gisvold, 1991; Abrahum, 2003; Supran et al., 2003).